Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
2019
Background
Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
72
References
6
Citations
NaN
KQI